Espinoza Octavio's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Sep 24, 2024
- Accession no.
- 0002001011-24-000088
- Filed
- Sep 24, 2024
- Trade date
- Sep 20, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $132.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Espinoza OctavioCIK 0001905248 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2024 | Common Stock | SSaleDisposed | −200 | $103.98 | −$20,796 | 25,685 | Direct | |
| Sep 20, 2024 | Common Stock | SSaleDisposed | −275 | $103.86 | −$28,561.5 | 25,410 | Direct | |
| Sep 20, 2024 | Common Stock | SSaleDisposed | −800 | $103.95 | −$83,160 | 24,610 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.